June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Targeting Retinal Vascular Endothelial cells using rAAV Capsid Mutant Vectors
Author Affiliations & Notes
  • Ramesh Periasamy
    Department of Ophthalmology and Visual Science, Medical College of Wisconsin, Wisconsin, United States
  • Dwani Patel
    Department of Ophthalmology and Visual Science, Medical College of Wisconsin, Wisconsin, United States
  • Benyapa Khowpinitchai
    Department of Ophthalmology and Visual Science, Medical College of Wisconsin, Wisconsin, United States
    Carroll University, Wisconsin, United States
  • Shannon Boye
    Department of Ophthalmology, University of Florida, Florida, United States
  • Sanford Boye
    Department of Ophthalmology, University of Florida, Florida, United States
  • Daniel M Lipinski
    Department of Ophthalmology and Visual Science, Medical College of Wisconsin, Wisconsin, United States
    Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships   Ramesh Periasamy, None; Dwani Patel, None; Benyapa Khowpinitchai, None; Shannon Boye, None; Sanford Boye, None; Daniel Lipinski, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4480. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ramesh Periasamy, Dwani Patel, Benyapa Khowpinitchai, Shannon Boye, Sanford Boye, Daniel M Lipinski; Targeting Retinal Vascular Endothelial cells using rAAV Capsid Mutant Vectors. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4480.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal vascular endothelial cells (VEC) play a major role in retinal-homeostasis and their dysfunction underlies pathogenesis in vascular diseases affecting the eye, such as diabetic retinopathy (DR) and exudative age-related macular degeneration (AMD). While numerous pre-clinical trials have shown that recombinant adeno-associated virus (rAAV) vectors can successfully mediate gene delivery to cells of the neural retina, targeting VECs remains particularly challenging. In this study, we examine whether incorporation of endothelial targeting peptides into the rAAV capsid increases VEC transduction efficiency using an ex vivo primary culture model.

Methods : VEC targeting capsid mutant rAAV2/2, 2/2[QuadYF-TV] and rAAV2/9 serotype vectors (n=10 per serotype) packaging a green fluorescent protein (GFP) reporter gene were created through introduction of a heptameric targeting peptide (7AA) at position 588 (2/2 and 2/2[QuadYF-TV] or 589 (2/9) of the virus protein (VP1-3). The infectivity and packaging efficiency of the newly generated VEC targeting vectors was first assessed on cultures of human embryonic kidney (HEK) 293T cells (N=3 wells per vector) using a picogreen dsDNA quantitation assay, fluorescence microscopy and flow cytometry. All infectious vectors were subsequently applied (MOI=100,000) to cultures of primary bovine VECs. After 72 hours, cells were fixed with 4% paraformaldehyde, stained with CD31 and transduction efficiency quantified using flowcytometry.

Results : The majority of VEC targeting mutants packaged successfully, although at lower titres that unmodified rAAV2/2 and 2/9 serotypes, and were capable of infecting HEK293T cells. CD31 labeling confirmed that ~75% of cells isolated from bovine retinae using our protocol were VECs. Three rAAV2/2 and rAAV2/2[QuadYF-TV) mutants (5, 6 and 8) were observed to have improved expression in VECs; rAAV2/9 mutants are being screened currently.

Conclusions : The development of rAAV vectors that efficiently target retinal VECs has the potential to substantially improve the treatment of ocular diseases, such as DR and AMD.Our preliminary findings indicate that incorporation of an endothelial targeting peptide into an exposed surface loop of the rAAV capsid may potentially improve the efficiency of gene delivery to VECs.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×